Etoposide is a cytotoxic agent, which has been used in the treatment of a variety of malignant conditions, such as neuroblastomas, small-cell lung cancer, leukaemia, lymphomas and gynaecological malignancies. It is a semisynthetic derivative of podophyllotoxin and acts by inhibiting mitosis. 1, 2 Common side effects are dose-limiting myelosuppression, alopecia and gastrointestinal toxicity. Although rare, hypersensitivity reaction to etoposide has been reported in 1-3% of patients. It is a type I hypersensitivity reaction, manifested by dyspnoea, chest discomfort, bronchospasm, hypotension, hypertension and skin flushing. 3 We report here the outcome of a patient who experienced hypersensitivity to etoposide phosphate but tolerated a subsequent intravenous administration of the same drug using a desensitisation protocol, enabling optimal treatment of his relapsed Hodgkin lymphoma.
A 25-year-old man was diagnosed with stage IIIA Hodgkin lymphoma, nodular sclerosing type. He was a smoker with no significant medical history and no known allergies. He achieved metabolic remission by Positron Emission Tomography (PET) after five of a planned six cycles of ABVD (doxorubicin 25 mg/m 2 , bleomycin 10 U/m 2 , vinblastine 6 mg/m 2 , dacarbazine 375 mg/ m 2 ). The last cycle was withheld because of a fall in left ventricular ejection fraction from 60 to 44%, which had returned to normal when the echocardiogram was repeated 3 months later. Six years after initial diagnosis, the patient developed cervical lymphadenopathy and stage III relapsed Hodgkin lymphoma was confirmed by cervical lymph node excision biopsy and PET scan. The patient was admitted to the hospital for salvage treatment with the regimen Moskowitz ICE (ifosfamide 5000 mg/m 2 , carboplatin AUC = 5 capped at 800 mg, etoposide phosphate 100 mg/m 2 ). Five minutes after starting the first dose of etoposide phosphate, the patient complained of feeling unwell, hot, dizzy and sweaty. Subsequently he reported a metallic taste in the mouth, chest tightness and difficulty breathing. The etoposide infusion was stopped immediately. On physical examination, blood pressure was 153/78 mm Hg, pulse rate was 107 beats per minute, chest was clear, breathing rate was 18/min and oxygen saturation was 91%. There was an erythematous rash covering 50% of the body surface area. Hydrocortisone and promethazine were administrated. A chest X-ray and an electrocardiogram were normal. A diagnosis of hypersensitivity reaction to etoposide phosphate was made and the ICE regimen was abandoned. High-dose therapy with autologous stem cell rescue was planned. The conditioning regimen selected was the BEAM (carmustine 300 mg/m 2 , cytarabine 200 mg/m 2 twice day, etoposide 200 mg/ m 2 , melphalan 140 mg/m 2 ) regimen despite the patient's immediate hypersensitivity reaction to etoposide. This decision was made considering evidence supporting BEAM as the optimal high-dose therapy for relapsed Hodgkin lymphoma, whereas second-line treatment may be less effective. 4, 5 After consultation with immunologists, a rapid desensitisation programme for etoposide phosphate infusion was devised, modelled on a previously published antibiotic desensitisation protocol. 6 The patient started on montelukast 10 mg daily and loratadine 10 mg twice a day two days prior the protocol start. The protocol used consists of three solutions administered sequentially starting with a 1:100 dilution, then a 1:10 dilution and a standard concentration of the allergen medication. The protocol is summarised in Table 1 . The protocol was administered as an inpatient and the intensive care unit was alerted before commencing.
The patient felt well throughout the administration of the preparative regimen and vital signs remained within normal limits. The patient completed the BEAM regimen without complications and remains in remission 12 months following completion of treatment.
Hypersensitivity reactions to medications can result in anaphylaxis due to IgE-mediated activation of mast cells with subsequent release of preformed inflammatory mediators, such as histamine, arachidonic acid metabolites and prostaglandins. Hypersensitivity to etoposide is rare but potentially life threatening. Most reactions are manifested during the first 5-10 min of the first treatment cycle and complete recovery is usual once the infusion is interrupted. Risk factors for developing hypersensitivity reactions have not been identified, and in a few of the reported cases patients had a history of drug allergy. 7 The aetiology and the exact mechanism are not fully understood. Typically, type I reactions occur, but type II reactions have also been described. 3, 8 Many investigators have attributed hypersensitivity reactions to epipophyllotoxins in part to additives used in formulating the drug. In particularly, benzyl alcohol and polysorbate 80, the vehicle used to dissolve the etoposide, is considered responsible for this reaction. 3 Etoposide phosphate, a water soluble prodrug of etoposide, which does not contain polysorbate 80, has been formulated to avoid problems associated with etoposide and has been used successfully to overcome hypersensitivity reaction to etoposide. 7, 9, 10 We report the case of a patient who developed an immediate hypersensitivity reaction during his first infusion of etoposide phosphate. Subsequently we elected to overcome this patient's hypersensitivity using a desensitization protocol. The BEAM regimen was selected on the basis of evidence supporting its use as the optimal preparative regimen for , etoposide 100 mg/m 2 ), BuCy (busulfan 1 mg/kg, cyclophoshpamide 60 mg/kg) and TBI (200 cGy) have shown that BEAM was associated with better overall survival. In fact the incidence of transplantation-related mortality at 1 year with BEAM was 4%, whereas it was 7% with CBV low , 8% with CBV high , 7% with BuCy and 8% after TBI. The probabilities of 3-year overall survival were BEAM 79%, CBV low 73%, CBV high 68%, BuCy 65% and TBI 47%. 4, 5 Given the apparent survival benefit observed with BEAM compared with non-etoposide regimens such as Bu/Cy, and after discussion with the patient, it was decided that the potential benefit from the use of the optimal conditioning regimen outweighed the risk associated with an etoposide desensitisation procedure.
Rapid drug desensitisation is a method that leads to a temporary clinical tolerance to a drug by administering small, gradually increasing doses to complete the total therapeutic dose of drug allergen. 10 This procedure causes a short-term insensitivity and consequently patients must be re-desensitised any time they are exposed to the allergenic medication. The molecular mechanisms inducing the temporary tolerance have been investigated and are partially known. 11 Rapid drug desensitisation induces mast cell tolerance to antigen probably through the molecular stabilisation of membrane bound IgE receptors carrying the antigen being desensitised; consequently no new inflammatory mediators are generated.
This case highlights that hypersensitivity reactions to etoposide phosphate do occur, albeit at lower frequency than conventional etoposide preparations. Furthermore, a desensitisation protocol was able to overcome hypersensitivity and enable optimal therapy for this patient's relapsed Hodgkin lymphoma.
